Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)
South Korea · Delayed Price · Currency is KRW 9,810.00
-190.00 (-1.90%)
At close: Oct 2, 2026
Ahn-Gook Pharmaceutical Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 111,494 | 96,151 | 74,216 | 106,948 | 104,448 | 122,613 | |
Market Cap Growth | 26.58% | 29.56% | -30.61% | 2.39% | -14.82% | -17.69% |
Enterprise Value | 125,617 | 114,723 | 118,816 | 100,255 | 81,429 | 96,410 |
Last Close Price | 9810.00 | 8460.00 | 6074.77 | 8177.38 | 7791.85 | 8865.08 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 5.15 | 12.85 | 4.41 | 82.90 | 15.19 | 31.13 |
Forward PE | - | 71.34 | 71.34 | 71.34 | 71.34 | 71.34 |
PS Ratio | 0.32 | 0.31 | 0.27 | 0.46 | 0.51 | 0.75 |
PB Ratio | 0.62 | 0.58 | 0.45 | 0.71 | 0.68 | 0.80 |
P/TBV Ratio | 0.67 | 0.61 | 0.46 | 0.72 | 0.69 | 0.82 |
P/FCF Ratio | 3.83 | 2.58 | - | - | - | - |
P/OCF Ratio | 2.83 | 2.11 | 15.10 | - | 58.40 | 83.29 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.36 | 0.37 | 0.44 | 0.43 | 0.40 | 0.59 |
EV/EBITDA Ratio | 4.00 | 6.18 | 8.27 | 9.94 | 5.69 | 28.16 |
EV/EBIT Ratio | 5.69 | 11.71 | 17.79 | 19.81 | 8.68 | - |
EV/FCF Ratio | 4.32 | 3.08 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.43 | 0.44 | 0.47 | 0.12 | 0.13 | 0.13 |
Debt / EBITDA Ratio | 2.37 | 3.93 | 5.41 | 1.75 | 1.40 | 5.90 |
Debt / FCF Ratio | 2.68 | 1.96 | - | - | - | - |
Net Debt / Equity Ratio | 0.07 | 0.11 | 0.29 | -0.12 | -0.12 | -0.18 |
Net Debt / EBITDA Ratio | 0.40 | 1.02 | 3.34 | -1.76 | -1.29 | -7.97 |
Net Debt / FCF Ratio | 0.45 | 0.51 | -0.68 | 2.61 | 16.14 | 10.64 |
Asset Turnover | 1.09 | 1.00 | 1.00 | 1.01 | 0.93 | 0.77 |
Inventory Turnover | 2.50 | 2.22 | 2.57 | 2.99 | 3.13 | 2.69 |
Quick Ratio | 1.12 | 1.00 | 1.15 | 1.25 | 1.53 | 1.75 |
Current Ratio | 1.69 | 1.65 | 1.75 | 1.73 | 1.98 | 2.23 |
Return on Equity (ROE) | 12.63% | 4.42% | 10.33% | 0.65% | 4.47% | 2.47% |
Return on Assets (ROA) | 4.67% | 2.00% | 1.54% | 1.37% | 2.64% | -0.32% |
Return on Invested Capital (ROIC) | 10.44% | 4.67% | 3.11% | 0.88% | 6.67% | -0.87% |
Return on Capital Employed (ROCE) | 9.80% | 4.30% | 3.00% | 3.20% | 5.80% | -0.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 19.42% | 7.78% | 22.70% | 1.21% | 6.58% | 3.21% |
FCF Yield | 26.10% | 38.71% | -95.63% | -6.36% | -1.09% | -2.09% |
Payout Ratio | 33.22% | 66.85% | 14.84% | 193.81% | 36.52% | 64.00% |
Buyback Yield / Dilution | 0.06% | 0.01% | -0.01% | 0.12% | 0.65% | 9.44% |
Total Shareholder Return | 4.55% | 0.01% | -0.01% | 0.12% | 0.65% | 9.44% |